2023
DOI: 10.1186/s12885-023-11180-y
|View full text |Cite
|
Sign up to set email alerts
|

Predicting survival for patients with mesothelioma: development of the PLACE prognostic model

Abstract: Introduction The overall survival of patients with mesothelioma is poor and heterogeneous. At present, the prediction model for Chinese patients needs to be improved. We sought to investigate predictors of survival in malignant pleural mesothelioma and develop prognostic prediction models. Methods This Two-center retrospective cohort study recruited patients with pathologically diagnosed mesothelioma at Beijing Chao-Yang Hospital and Beijing Tong-R… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 71 publications
0
2
0
Order By: Relevance
“…This highlights the need for a more effective diagnostic method for MM that can detect the disease at an earlier and potentially more treatable stage. Currently, MM has a median survival time between 8-and 14-months following diagnosis [5] Early detection of MM could lead to better patient outcomes and enable further research into potential curative treatments to be conducted on patients with earlier stage disease.…”
Section: Introductionmentioning
confidence: 99%
“…This highlights the need for a more effective diagnostic method for MM that can detect the disease at an earlier and potentially more treatable stage. Currently, MM has a median survival time between 8-and 14-months following diagnosis [5] Early detection of MM could lead to better patient outcomes and enable further research into potential curative treatments to be conducted on patients with earlier stage disease.…”
Section: Introductionmentioning
confidence: 99%
“…Many of these parameters are included in the more widely used score systems for PM, namely, that of the European Organization for Research and Treatment of Cancer (EORTC) and Cancer and Leukemia Group B (CALGB). They have been introduced over 20 years ago and remain valid, although many studies have attempted to update them, identify additional prognostic biomarkers, and develop models that combine clinical and molecular features [21,22].…”
Section: Introductionmentioning
confidence: 99%